

**DRUGS COVERED UNDER THE  
MEDICARE REPLACEMENT DRUG DEMONSTRATION**  
*(updated August 30, 2004)*

<b>Demonstration Covered Indication</b>	<b>Drug/Biological—Compound Name (Brand Name)</b>
<b>Rheumatoid Arthritis</b>	<b>Adalimumab (Humira)</b>
	<b>Anakinra (Kineret)</b>
	<b>Etanercept (Enbrel)</b>
<b>Multiple Sclerosis</b>	<b>Glatiramer acetate (Copaxone)</b>
	<b>Interferon beta –1a (Rebif, Avonex)</b>
	<b>Interferon beta –1b (Betaseron)</b>
<b>Post Menopausal Osteoporosis (patient must be homebound)</b>	<b>Calcitonin – nasal (Miacalcin – nasal)</b>
	<b>Risedronate (Actonel)</b>
<b>Pulmonary Hypertension</b>	<b>Bosentan (Tracleer)</b>
<b>Secondary Hyperparathyroidism</b>	<b>Doxercalciferol (Hectoral)</b>
<b>Paget's Disease</b>	<b>Alendronate (Fosamax)</b>
	<b>Risedronate (Actonel)</b>
<b>Hepatitis C</b>	<b>Pegylated interferon alfa-2a (Pegasys)</b>
	<b>Pegylated interferon alfa-2b (PEG-Intron)</b>
<b>CMV Retinitis</b>	<b>Valcyte (Valganciclovir)</b>
<b>Acromegaly</b>	<b>Pegvisomant (Somavert)</b>
<b>Anti-Cancer</b>	
<b>Cutaneous T-cell Lymphoma</b>	<b>Bexarotene (Targretin)</b>
<b>Non-small cell lung cancer</b>	<b>Gefitinib (Iressa)</b>
<b>Epithelial ovarian cancer</b>	<b>Altretamine (Hexalen)</b>
<b>Chronic Myelogenous Leukemia</b>	<b>Imatinib Mesylate (Gleevec)</b>
<b>GI Stromal Tumor</b>	<b>Imatinib Mesylate (Gleevec)</b>
<b>Multiple Myeloma</b>	<b>Thalidomide (Thalomid)</b>
<b>Breast Cancer</b>	<b>Hormonal therapy</b>
<b>Stage 2-4 only</b>	<b>Anastrozole (Arimidex)</b>
	<b>Exemestane (Aromasin)</b>
	<b>Letrozole (Femara)</b>
	<b>Tamoxifen (Nolvadex)</b>
	<b>Toremifene (Fareston)</b>
<b>Prophylactic agent to reduce ifosfamide-induced hemorrhagic cystitis</b>	<b>Mesna (Mesnex)</b>